A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)

A Double-Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of a Refrigerator-Stable Formulation of Zoster Vaccine Live (Oka/Merck)

The purpose of this study is to determine whether the refrigerator-stable formulation of an investigational vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile to that of the freezer-stable formulation of the vaccine.

The duration of treatment is 4 weeks.

Inclusion Criteria:

• Individuals who are at least 50 years of age or older with a history of varicella (chicken pox)

Exclusion Criteria:

• Prior history of herpes zoster (shingles)
• Prior receipt of varicella or zoster vaccine
• Immunosuppressed